Evaluating Value Beyond Efficacy: A Meta-Analytic Assessment of Inclisiran’s Cost-Effectiveness in Cardiovascular Prevention
Alexandra Maștaleru, Muthana Zouri, Maria Magdalena Leon, Gabriela Popescu, Nicoleta Zouri, Bogdan Ionel Tamba, Carmen Marinela Cumpăt, Fabrizio Cedrone · 2025
Read Evaluating Value Beyond Efficacy: A Meta-Analytic Assessment of Inclisiran’s Cost-Effectiveness in Cardiovascular Prevention by Alexandra Maștaleru, Muthana Zouri, Maria Magdalena Leon, Gabriela Popescu, Nicoleta Zouri, Bogdan Ionel Tamba, Carmen Marinela Cumpăt, Fabrizio Cedrone (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12733213.txt.
Description
Inclisiran is a newer drug that lowers blood cholesterol, and Alexandra Maștaleru and a team of co-authors pool the published studies asking whether it is worth its price. Heart and artery disease still causes about forty percent of deaths worldwide, and mixing several drugs can cut cholesterol far more than one drug alone, yet risk remains for many patients. The review gathers studies that report health gains in quality-adjusted life years alongside costs.
The value of the drug turned out to depend heavily on place: local prices, patient risk, and health system capacity all shifted the answer. It looked worthwhile in richer settings and for high-risk patients, but not for broad first-line prevention. The authors urge risk-based targeting and price talks.
Catalog record
| CREATOR | Alexandra Maștaleru, Muthana Zouri, Maria Magdalena Leon, Gabriela Popescu, Nicoleta Zouri, Bogdan Ionel Tamba, Carmen Marinela Cumpăt, Fabrizio Cedrone |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |